Cargando…
P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA
Autores principales: | Garcia Gutierrez, Valentin, Carlos Hernandez-Boluda, Juan, Felipe Casado Montero, Luis, Gómez Casares, M Teresa, Ayala Diaz, Rosa, Xicoy Cirici, Blanca, Ferrer-Marín, Francisca, Ortí, Guillermo, De Paz Arias, Raquel, Ossorio Prendes, Santiago, Pérez López, Raúl, Mora Castera, Elvira, Ruiz Nuño, Concepcion, Jimenez, Antonio, Boque Genovard, Concepcion, Sierra, Magdalena, Martinez-Lopez, Joaquín |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429600/ http://dx.doi.org/10.1097/01.HS9.0000969624.77404.fb |
Ejemplares similares
-
S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS
por: José Cuenca Zamora, Ernesto, et al.
Publicado: (2023) -
Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
por: Marcé, Sílvia, et al.
Publicado: (2021) -
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
por: Luna, A., et al.
Publicado: (2022) -
Ponatinib‐induced ichthyosiform eruption
por: Kluger, Nicolas, et al.
Publicado: (2021) -
PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI
por: Torra, Silvia Marce, et al.
Publicado: (2023)